Targeting menin: a promising therapeutic strategy for susceptible acute leukemia subtypes
Por um escritor misterioso
Descrição
Experimental, precision strategy targets unique cancer protein found in certain acute myeloid leukemia cases
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
Menin inhibitor resistance is associated with the emergence of MEN1
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study - The Lancet Haematology
Recent Progress of Small Molecule Menin–MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia
City of Hope presents pivotal clinical trial data at American Society of Hematology (ASH) conference on revumenib, a potential new targeted therapy for high-risk subtypes of acute leukemias
Recent Progress of Small Molecule Menin–MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia
Acute myeloid leukemia - Wikipedia
A Novel Approach Towards a Vaccine for Relapsing Acute Myeloid Leukemia: Q&A with Dr. Karin Gaensler - BroadcastMed
SEC Filing — Kura Oncology, Inc.
de
por adulto (o preço varia de acordo com o tamanho do grupo)
